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O. Manuel*, P. Tarr, J-P. Venetz, M. Trande[enburg, 
P. Mey[an, M. PascuaL Centre Hospitalier 
Universitaire Vaudois, CHUV, 1011 Lausanne, 
Switzerland 
Background: There is an increasing amount of 
data associating MBL deficiency with a higher sus- 
ceptibility to meningococca[ disease. In addition, 
meningococca[ disease has been reported in pa- 
tients with various immunosuppressive conditions. 
However, to our knowledge, only three cases of 
meningococca[ disease have been reported in solid 
organ recipients (SOT). 
Methods & Results: A 32 year-old male patient un- 
derwent cadaveric kidney transplantation for end- 
stage renal disease of unknown origin. On day 71 
post-transplantation he developed fever (39.6°C), 
shaking chilis, and tachycardia without hypoten- 
sion. At this time, immunosuppression consisted 
of tacro[imus, prednisone 10mg daily and my- 
copheno[ate mofeti[ 2 g daily. Physical examination 
on admission was normal, except for two small 
petechia[ lesions on the forearm. No meningeal 
signs were present. Three sets of blood cultures 
grew Neisseria meningitidis group C susceptible to 
ceftriaxone (MIC=0.003mg/[). Antibiotic therapy 
consisted in intravenous ceftriaxone 2 g per day for 
a total duration of 7 days. Serum immunog[obu[in 
levels, C3, C4 and CHS0 were normal However, us- 
ing a method to screen for the functional activity of 
a[[ three pathways of complement (Wies[ab, Lund, 
Sweden), no activation via the MBL pathway could 
be detected (0%). A subsequent quantification of 
MBL pathway components revealed normal levels 
of MASP 2 but undetectab[e amounts of MBL (below 
10 ng/m[, normal range: >500 ng/m[). 
Conclusion: Since the exact incidence and the pos- 
sible relationship between meningococca[ disease 
and organ transplantation is not we[[ understood, 
we strongly encourage transplantation centers to 
report additional cases. The potential clinical use- 
fu[ness of screening SOT candidates for MBL defi- 
ciency in relation to infectious complications after 
transplantation remains to be determined. 
Abstracts 
30 
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Background: Immunosuppressive and antivira[ pro- 
phy[actic drugs are needed to prevent acute re- 
jection and infection after organ transplantation. 
We assessed the effectiveness of a new combined 
regimen introduced at our transplantation center. 
Methods: We reviewed at[ consecutive patients 
who underwent kidney transplantation at our in- 
stitution over a 5.5-year period, with a follow-up 
of at [east 6 months. Patients transplanted from 
1/2000 to 3/2003 (Period 1) were compared to 
patients transplanted from 4/2003 to 7/2005 (Pe- 
riod 2). In period 1, patients were treated with 
Basi[iximab, Cic[osporin, steroids and Mycophe- 
notate or Azathioprine. Prophylaxis with Va[aci- 
c[ovir was prescribed in CMV D+/R- patients; oth- 
erwise, a preemptive antivira[ approach was used. 
In period 2, immunosuppressive drugs were Basi[- 
iximab, Tacro[imus, steroids and Mycopheno[ate. 
A 3-month CMV prophylaxis with Va[gancic[ovir was 
used, except in D-/R- patients. 
Results: Sixty-three patients were transplanted in 
period 1 and 70 patients in period 2. Baseline 
characteristics of both groups were comparable; 
in particular 17% of patients were CMV D+/R- in 
period 1 compared to 23% in period 2 (p=0.67). 
Acute rejection was more frequent in period 1 
than in period 2 (40% of patients vs 7%, respec- 
tively p<0.001). Nineteen patients (30%) in pe- 
riod 1 were diagnosed with CMV infection/disease 
that required treatment, compared with 8 patients 
(11.4%) in period 2 (p = 0.003). Of these 8 patients, 
at[ had CMV infection/disease after discontinuation 
of Va[gancic[ovir prophylaxis, 6 were D+/R- (75%), 
and at[ were treated with oral Va[gancic[ovir. There 
was no difference between periods in terms of 
incidence of BK nephropathy, post-transplant [ym- 
phopro[iferative disease, graft toss, and mortality. 
Conclusions: These results indicate that a 3-month 
course of oral Va[gancic[ovir is very effective to 
prevent CMV infection/disease in kidney transplan- 
tation. Late-onset CMV disease is a residual prob- 
lem in D+/R- patients receiving VGC prophylaxis. 
